Synapse - Global Drug Intelligence Database

Try LifeScience Products:

AI-Powered

Pharmaceutical Intelligence

Access to drugs, clinical trials, patents, literatures and news in one search

Try:

AL-102 (Ayala)Crohn DiseasePneumococcal InfectionsFGFRL1APOC3Pfizer Inc.

86

K

Drugs & Biologics

46

K

Targets

978

K

Organizations

922

K

/

171

K

Clinical Trials / Results

66

M

Literatures

16

M

Patents

Recent blog posts

View all blog posts →

selectION Reveals Encouraging Outcomes from Early-Stage Trial Testing si-544 on Individuals with Eczema

3 min read

selectION Reveals Encouraging Outcomes from Early-Stage Trial Testing si-544 on Individuals with Eczema

30 April 2024

selectION, Inc. has shared encouraging outcomes from its initial human Phase 1b study concerning its primary drug, si-544, targeted at individuals with atopic dermatitis.

Exploring the Chemical Diversity of Macrocyclic Oligoamides

7 min read

Exploring the Chemical Diversity of Macrocyclic Oligoamides

30 April 2024

This paper reported an innovative computational approach that successfully achieved the design and prediction of macrocyclic oligoamides composed of alpha, beta, gamma, and other non-natural amino acid backbone chemical structures.

AriBio Granted EMA Approval for Phase 3 Trials of AR1001 in Alzheimer’s Treatment (POLARIS-AD)

3 min read

AriBio Granted EMA Approval for Phase 3 Trials of AR1001 in Alzheimer’s Treatment (POLARIS-AD)

30 April 2024

AriBio Granted EMA Approval for Phase 3 Trials of AR1001 in Alzheimer’s Treatment (POLARIS-AD).

Check out our latest report

View all reports →

Global Drug R&D Express (Jan 2024)

Global Drug R&D Express (Jan 2024)

This report compiles and summarizes the basic information of all the first-to-market and special review drugs globally for the month of December, totaling 68 drugs. Among them, 2 first-to-market drugs and 3 drugs under special review were selected for detailed analysis. The report provides an in-depth interpretation of these drugs, covering various aspects such as basic information, development status, technological barriers, mechanism of action, clinical trials, and competitive landscape.

Global Drug R&D Express (Dec 2023)

Global Drug R&D Express (Dec 2023)

This report compiles and summarizes the basic information of all the first-to-market and special review drugs globally for the month of December, totaling 104 drugs. Among them, 2 first-to-market drugs and 5 drugs under special review were selected for detailed analysis. The report provides an in-depth interpretation of these drugs, covering various aspects such as basic information, development status, technological barriers, mechanism of action, clinical trials, and competitive landscape.

Global Drug R&D Express (Nov 2023)

Global Drug R&D Express (Nov 2023)

This report compiles and summarizes the basic information of all the first-to-market and special-review medicines globally in November, totaling 104. From these, 5 first-to-market medicines and 5 special-review medicines have been meticulously selected. The report provides a detailed interpretation of these medicines, covering multiple aspects such as their basic information, development status, technological barriers, mechanisms of action, clinical trials, and competitive landscape.

Latest news

View all news →

news cover

SELLAS Announces Positive Phase 2 Preliminary Data of SLS009 in r/r AML Achieving a 100% Response Rate in Patients with ASXL1 Mutation At the Optimal Dose Level

5 hours ago

news cover

Palisade Bio’s Lead Product Candidate, PALI-2108 Demonstrates Potent Anti-Inflammatory Effects in Ex-Vivo Study of Whole Blood Samples Challenged with Pro-Inflammatory Lipopolysaccharide (LPS)

6 hours ago

news cover

HiberCell Announces First Patient Dosed in Clinical Collaboration with Merck, Evaluating HC-7366 in Combination with WELIREG® (belzutifan) in patients with advanced ccRCC

6 hours ago

news cover

Medicenna Therapeutics Announces Closing of CA$20 Million Investment from RA Capital Management

8 hours ago

Who We Serve

View our solutions →

01

R&D Decision Makers

R&D Decision Makers

We provide R&D decision makers with access to accurate, connected data so they can quickly understand newly-emerged technology trends, have an insight into the competitive landscapes, uncover partnership opportunities, and decide the direction of innovation.

02

Business Development Professionals

Business Development Professionals

We provide 320,000+ life science organizations with drug pipeline and investment history, which help you make informed decisions on potential partnerships or acquisition targets.

03

Pharmaceutical Analyst

Pharmaceutical Analyst

We accelerate the research process for Pharmaceutical Analysts through various connected data, including drug approval, clinical trials, patent, non-patent literature and news. Synapse provides users with a 360-degree view of the competitive and technology landscape!

LifeScience Product Suite

Synapse

Looking for drug development opportunities

Evaluate the value of license-in projects

Screen investment targets

Optimize product pipeline

Current product

Chase new frontiers in bio-innovation

Stay on top of competitor movements

Validate novelty and freedom to operate searches with ease

Identify sequences for therapeutic activities

Explore promising compounds and their applications

Accelerate novelty and freedom to operate reviews

Strengthen competitor analysis

Get started for free today!

Access to drugs, clinical trials, patents, literatures and news in one search.